Who are Maraviroc + Zidovudine/Lamivudine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/maraviroc-zidovudine-lamivudine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Maraviroc + Zidovudine/Lamivudine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maraviroc + Zidovudine/Lamivudine (Maraviroc + Zidovudine/Lamivudine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR5 antagonist + nucleoside reverse transcriptase inhibitors (NRTIs). Area: Infectious Disease / Virology.

phase 3 CCR5 antagonist + nucleoside reverse transcriptase inhibitors (NRTIs) CCR5 co-receptor; HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Maraviroc + Zidovudine/Lamivudine (Maraviroc + Zidovudine/Lamivudine) — ViiV Healthcare. This combination blocks HIV entry into CD4+ T cells via CCR5 antagonism while simultaneously inhibiting reverse transcriptase to suppress viral replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Maraviroc + Zidovudine/Lamivudine TARGET	Maraviroc + Zidovudine/Lamivudine	ViiV Healthcare	phase 3	CCR5 antagonist + nucleoside reverse transcriptase inhibitors (NRTIs)	CCR5 co-receptor; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR5 antagonist + nucleoside reverse transcriptase inhibitors (NRTIs) class)

ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maraviroc + Zidovudine/Lamivudine — Competitive Intelligence Brief. https://druglandscape.com/ci/maraviroc-zidovudine-lamivudine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab